Association of Mu-Opioid Receptor Expression With Long-Term Survival and Perineural Nerve Invasion in Patients Undergoing Surgery for Ovarian Cancer

Hao Zhang; Hao Zhang; Mengdi Qu; Mengdi Qu; Caihong Sun; Caihong Sun; Yanghanzhao Wang; Yanghanzhao Wang; Ting Li; Ting Li; Wei Xu; Zhirong Sun; Zhirong Sun; Xiaoguang Zhang; Xiaoguang Zhang; Xiaoguang Zhang; Kefang Guo; Kefang Guo; Wankun Chen; Wankun Chen; Minli Sun; Minli Sun; Changhong Miao; Changhong Miao; Changhong Miao

doi:10.3389/fonc.2022.927262

Frontiers in Oncology (Jul 2022)

Association of Mu-Opioid Receptor Expression With Long-Term Survival and Perineural Nerve Invasion in Patients Undergoing Surgery for Ovarian Cancer

Hao Zhang,
Hao Zhang,
Mengdi Qu,
Mengdi Qu,
Caihong Sun,
Caihong Sun,
Yanghanzhao Wang,
Yanghanzhao Wang,
Ting Li,
Ting Li,
Wei Xu,
Zhirong Sun,
Zhirong Sun,
Xiaoguang Zhang,
Xiaoguang Zhang,
Xiaoguang Zhang,
Kefang Guo,
Kefang Guo,
Wankun Chen,
Wankun Chen,
Minli Sun,
Minli Sun,
Changhong Miao,
Changhong Miao,
Changhong Miao

Affiliations

Hao Zhang: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Hao Zhang: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Mengdi Qu: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Mengdi Qu: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Caihong Sun: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Caihong Sun: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Yanghanzhao Wang: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Yanghanzhao Wang: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Ting Li: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Ting Li: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Wei Xu: Department of Anesthesiology, Jinshan Hospital, Fudan University, Shanghai, China
Zhirong Sun: Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China
Zhirong Sun: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Xiaoguang Zhang: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Xiaoguang Zhang: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Xiaoguang Zhang: Department of Anesthesiology, Jinshan Hospital, Fudan University, Shanghai, China
Kefang Guo: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Kefang Guo: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Wankun Chen: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Wankun Chen: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Minli Sun: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Minli Sun: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Changhong Miao: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
Changhong Miao: Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China
Changhong Miao: Department of Anesthesiology, Jinshan Hospital, Fudan University, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2022.927262
Journal volume & issue: Vol. 12

Abstract

Read online

BackgroundOpioids are widely used during primary debulking surgery (PDS) for ovarian cancers, and a high mu-opioid receptor (MOR) expression predicts worse cancer outcomes. However, the impact of MOR expression on survival outcomes in ovarian cancers is still not clear.MethodsA retrospective cohort study was conducted in patients who underwent PDS in ovarian cancer patients. MOR expression was measured in tumor and normal tissue. Primary outcomes were overall survival (OS) and disease-free survival (DFS). Secondary outcomes included perineural invasion (PNI), intraoperative sufentanil consumption, length of stay (LOS), and verbal numerical rating scale (VNRS) on postoperative day 1 (POD1), POD3, and POD5.ResultsAfter propensity score matching, a total of 366 patients were finally enrolled in this study. There were no significant differences in OS rates in patients with high versus low levels of MOR (1-year OS: 82.9% versus 83.3%, 3-year: 57.8% versus 59.1%, 5-year: 22.4% versus 23.1%,respectively) in the ovarian cancers. There were no significant differences in DFS between the groups. Intraoperative sufentanil consumption was higher in the MOR high-expression group compared with the MOR low-expression group. Tumors expressing high levels of MOR showed higher rates of PNI. VNRS in the MOR high-expression group was higher on POD1.ConclusionMOR is not an independent predictor of worse survival in ovarian cancers but is associated with high rates of perineural invasion.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords